Flying The Web For News.
Featured Guest Posts
Dropshipping Guide
Shopify E-commerce Guide
Microsoft Exam Study
Business Opportunity Ideas
Microsoft Jobs News
Microsoft Exam
Writing Service Review
Slot Game Review
Data Recovery Review
Publicaciones Destacadas
Como ganar dinero por Internet
+ Larger Font | - Smaller Font
Share


COVID-19 Map Tracker | COVID-19 News Features


Globe NewsWire News Distribution Service


TOKYO and CAMBRIDGE, United Kingdom, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, has been notified by its partner Neurocrine Biosciences Inc. (“Neurocrine”; Nasdaq: NBIX) that the U.S. Food and Drug Administration (FDA) Investigational New…


Posted: 2022-08-04 23:05:00

Get Full News Story On GlobeNewsWire Press Release Service



Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.



Related News Stories From The Web And More

Related Bing News Search Results

Press Release: Sosei Heptares’ Oral, Selective M4 Receptor Agonist Advancing into Phase 2 Clinical Development under Multi-Program Collaboration with Neurocrine Biosciences - Newscast

Cyclo Therapeutics to Present at the China NPC Association Meeting

Mon, 08 Aug 2022 05:06:00 GMT Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation ...

Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q2 2022 Results - Earnings Call Transcript

Thu, 04 Aug 2022 17:24:00 GMT Q2 2022 Earnings Conference Call August 04, 2022 04:30 PM ET Company Participants Todd Tushla - Vice President of Investor Relations ...

Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results

Thu, 04 Aug 2022 13:03:00 GMT Pipeline prioritizes tau antibody for Alzheimer’s disease and gene therapies for GBA1 Parkinson’s disease and SOD1 ALS, each program employing efficient paths to human proof of biology Targeting ...

Detailed Data From the Phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented at AAIC

Tue, 02 Aug 2022 08:00:00 GMT Crenezumab was safe and well tolerated with no cases of ARIA-E observed during the up to eight-year studyAs previously reported, numerical differences favoring crenezumab over placebo were confirmed ...

American Gene Technologies' HIV Cure Clinical Trial Enters Critical Phase: Withdrawing Participants from Antiretrovirals

Thu, 28 Jul 2022 07:00:00 GMT American Gene Technologies' HIV Cure Clinical Trial Enters Critical Phase: Withdrawing Participants from Antiretrovirals Jul (PRNewswire via ...

Related News Story Videos From Youtube



Blow Us A Whistle